AI-ECG for Preoperative Cardiovascular Risk Stratification Before General Surgery

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age20+
SponsorSeoul National University Bundang Hospital

About this trial

This randomized controlled trial evaluates whether an artificial intelligence-enhanced electrocardiography (AI-ECG)-based strategy for preoperative cardiovascular risk stratification is noninferior to usual care in patients undergoing elective general surgery. Eligible patients are randomly assigned to either an AI-ECG-guided preoperative assessment strategy or usual preoperative care.

The primary outcome is the incidence of major adverse cardiovascular events (MACE) within 30 days after surgery, defined as a composite of all-cause death, ventricular fibrillation/tachycardia or cardiac arrest, non-fatal myocardial infarction, unplanned revascularization (PCI or CABG), mechanical ventilation for ≥3 days, and acute heart failure requiring intravenous diuretics.

Secondary outcomes include the rate of preoperative cardiac imaging and functional testing (echocardiography, coronary CT, SPECT, stress test), the rate of preoperative cardiology consultation, length of hospital stay, direct medical costs, and the time required for preoperative evaluation. The study aims to determine whether AI-ECG can safely guide preoperative cardiovascular evaluation while reducing unnecessary testing, resource use, and cost.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adults aged 20 years or older

Patients scheduled for elective (non-emergent) general surgery

Willing and able to provide voluntary written informed consent

Disqualifiers

Emergency surgery

Surgery under local anesthesia

Trial design

Design model

Parallel

Treatments tested in this trial

  • AI-ECG-based preoperative risk stratification (ECG Buddy)

    Diagnostic test

    A standard 12-lead ECG is analyzed by an AI-enhanced ECG algorithm (ECG Buddy) to stratify preoperative cardiovascular risk. Designated AI-ECG biomarkers are used as decision thresholds to guide subsequent preoperative cardiovascular evaluation and cardiology consultation.

Treatment groups

3,200 Participants
are divided into 2 treatment groups
Group A: AI-ECG-guided preoperative strategyExperimental treatment 1 intervention
Group B: Usual careNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

Incidence of major adverse cardiovascular events (MACE) within 30 days after surgery

Composite of all-cause death, ventricular fibrillation/tachycardia or cardiac arrest, non-fatal myocardial infarction, unplanned revascularization (PCI or CABG), mechanical ventilation for ≥3 days, and acute heart failure requiring intravenous diuretics.

Time frame
Within 30 days after surgery

Secondary outcomes

1

Rate of preoperative cardiac imaging and functional testing

Proportion of patients undergoing preoperative echocardiography, coronary CT, SPECT, or stress testing.

Time frame
From randomization to surgery, up to 24 weeks
2

Rate of preoperative cardiology consultation

Time frame
From randomization to surgery, up to 24 weeks
3

Length of hospital stay

Time frame
Through hospital discharge (up to 30 days)
4

Direct medical costs

Time frame
Within 30 days after surgery

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: